Transplacental hemophilia A and prophylactic treatment with intravenous immunoglobulin and recombinant factor VIIa in the newborn period: a case report


Gunel Karaburun I. E. , Kayki G., AYTAÇ S. A. , Celik H. T. , GÜMRÜK F. , Yigit Ş. S.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, vol.32, no.2, pp.151-154, 2021 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 32 Issue: 2
  • Publication Date: 2021
  • Doi Number: 10.1097/mbc.0000000000000978
  • Title of Journal : Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • Page Numbers: pp.151-154
  • Keywords: acquired hemophilia A, newborn, transplacental, ACQUIRED FACTOR-VIII, INHIBITORS, PREGNANCY

Abstract

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.Acquired hemophilia due to inhibitor antibodies to factor VIII (FVIII) is a very rare entity in neonatal period. Maternal IgG antibodies may cross the placenta and can cause life-threatening hemorrhages in newborns. Here, we represent a newborn who diagnosed as a transplacental acquired hemophilia A. A very high titer of inhibitor level (320 Nijmegen-Bethesda unit) was detected in plasma due to transplasental transfer in this case. According to the best of our knowledge the baby had the highest inhibitor level in neonatal period in the literature. Bleeding complications including intracranial hemorrhage secondary to this condition were reported before. Therefore, to prevent possible life complications, prophylactic recombinant FVIIa was administered in the presenting case and any bleeding event was not observed during follow-up. In conclusion, using prophylactic recombinant FVIIa in newborns is a safe choice for transplacental acquired hemophilia A.